Highlights from ASCO 2025 in early-stage NSCLC include updates on CheckMate 816 on neoadjuvant nivolumab, NeoADAURA on osimertinib, and data on low-dose CT screening, presented by Dr Jonathan Goldman. Medscape

Read the full article on medscape.com